Literature DB >> 28250114

C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.

Fu-Hsien Yu1,2, Kuo-Jung Huang2, Chin-Tien Wang3,2.   

Abstract

HIV-1 protease (PR) functions as a homodimer mediating virus maturation following virus budding. Gag-Pol dimerization is believed to trigger embedded PR activation by promoting PR dimer formation. Early PR activation can lead to markedly reduced virus yields due to premature Gag cleavage. The p6* peptide, located between Gag and PR, is believed to ensure virus production by preventing early PR maturation. Studies aimed at finding supporting evidence for this proposal are limited due to a reading frame overlap between p6* and the p6gag budding domain. To determine if p6* affects virus production via the modulation of PR activation, we engineered multiple constructs derived from Dp6*PR (an assembly- and processing-competent construct with Pol fused at the inactivated PR C terminus). The data indicated that a p6* deletion adjacent to active PR significantly impaired virus processing. We also observed that the insertion of a leucine zipper (LZ) dimerization motif in the deleted region eliminated virus production in a PR activity-dependent manner, suggesting that the LZ insertion triggered premature PR activation by facilitating PR dimer formation. As few as four C-terminal p6* residues remaining at the p6*/PR junction were sufficient to restore virus yields, with a Gag processing profile similar to that of the wild type. Our study provides supporting evidence in a virus assembly context that the C-terminal p6* tetrapeptide plays a role in preventing premature PR maturation.IMPORTANCE Supporting evidence for the assumption that p6* retards PR maturation in the context of virus assembly is lacking. We found that replacing p6* with a leucine zipper peptide abolished virus assembly due to the significant enhancement of Gag cleavage. However, as few as four C-terminal p6* residues remaining in the deleted region were sufficient for significant PR release, as well as for counteracting leucine zipper-incurred premature Gag cleavage. Our data provide evidence that (i) p6* ensures virus assembly by preventing early PR activation and (ii) four C-terminal p6* residues are critical for modulating PR activation. Current PR inhibitor development efforts are aimed largely at mature PR, but there is a tendency for HIV-1 variants that are resistant to multiple protease inhibitors to emerge. Our data support the idea of modulating PR activation by targeting PR precursors as an alternative approach to controlling HIV-1/AIDS.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Gag; human immunodeficiency virus; protease; virus assembly

Mesh:

Substances:

Year:  2017        PMID: 28250114      PMCID: PMC5411600          DOI: 10.1128/JVI.00103-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding.

Authors:  J M Louis; G M Clore; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1999-09

2.  Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1.

Authors:  M K Hill; C W Hooker; D Harrich; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor.

Authors:  Rieko Ishima; Dennis A Torchia; John M Louis
Journal:  J Biol Chem       Date:  2007-04-04       Impact factor: 5.157

Review 4.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

5.  Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing.

Authors:  G Zybarth; C Carter
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

6.  Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.

Authors:  H G Kräusslich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease.

Authors:  Chun Tang; John M Louis; Annie Aniana; Jeong-Yong Suh; G Marius Clore
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

8.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

Authors:  A M Mildner; D J Rothrock; J W Leone; C A Bannow; J M Lull; I M Reardon; J L Sarcich; W J Howe; C S Tomich; C W Smith
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162

9.  Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.

Authors:  N Whitehurst; C Chappey; C Petropoulos; N Parkin; A Gamarnik
Journal:  AIDS Res Hum Retroviruses       Date:  2003-09       Impact factor: 2.205

10.  Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

Authors:  Anna Figueiredo; Katie L Moore; Johnson Mak; Nicolas Sluis-Cremer; Marie-Pierre de Bethune; Gilda Tachedjian
Journal:  PLoS Pathog       Date:  2006-11       Impact factor: 6.823

View more
  10 in total

1.  HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity.

Authors:  Fu-Hsien Yu; Chin-Tien Wang
Journal:  Retrovirology       Date:  2018-04-14       Impact factor: 4.602

2.  Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.

Authors:  Liangqun Huang; Linfeng Li; ChihFeng Tien; Daniel V LaBarbera; Chaoping Chen
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

3.  Amino acid substitutions at the HIV-1 transframe region significantly impair virus infectivity.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

4.  Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package.

Authors:  Yi-Ru Lin; Shih-Ming Chu; Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  BMC Microbiol       Date:  2022-04-09       Impact factor: 3.605

5.  Enhanced Transmissibility and Decreased Virulence of HIV-1 CRF07_BC May Explain Its Rapid Expansion in China.

Authors:  Zetao Cheng; Huanchang Yan; Qingmei Li; Sherimay D Ablan; Alex Kleinpeter; Eric O Freed; Hao Wu; Emmanuel Enoch Dzakah; Jianhui Zhao; Zhigang Han; Haiying Wang; Shixing Tang
Journal:  Microbiol Spectr       Date:  2022-06-21

6.  Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors.

Authors:  ChihFeng Tien; Liangqun Huang; Susan M Watanabe; Jordan T Speidel; Carol A Carter; Chaoping Chen
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

7.  PYRE insertion within HIV-1 subtype C p6-Gag functions as an ALIX-dependent late domain.

Authors:  Devidas Chaturbhuj; Ajit Patil; Raman Gangakhedkar
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

8.  Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.

Authors:  Jana Humpolíčková; Jan Weber; Jana Starková; Eva Mašínová; Jana Günterová; Iva Flaisigová; Jan Konvalinka; Taťána Majerová
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

9.  HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  Viruses       Date:  2020-01-02       Impact factor: 5.048

10.  A Novel Network Science and Similarity-Searching-Based Approach for Discovering Potential Tumor-Homing Peptides from Antimicrobials.

Authors:  Maylin Romero; Yovani Marrero-Ponce; Hortensia Rodríguez; Guillermin Agüero-Chapin; Agostinho Antunes; Longendri Aguilera-Mendoza; Felix Martinez-Rios
Journal:  Antibiotics (Basel)       Date:  2022-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.